BUZZ-Axsome Therapeutics rises on migraine drug trial data

Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket

AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments

Symbravo is a combination of two medicines, meloxicam and rizatriptan

In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says

Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women

AXSM gained 6.3% in 2024